In a recent interview, Alexander Rau, M.D., discussed emerging research, presented at the recent RSNA conference, that shows the capability of diffusion microstructural imaging to differentiate subtle shifts in microstructural gray matter associated with common symptomatology of long Covid.
Long Covid may affect up to 41 percent of non-hospitalized adults who have had COVID-19, according to the Centers for Disease Control and Prevention (CDC).
However, diffusion microstructural imaging, a novel magnetic resonance imaging (MRI) technique, may provide improved insight into associations between microstructural changes in the brain and common Long Covid effects such as neurocognitive deficits, fatigue, and olfactory dysfunction, according to new research presented at the recent Radiological Society of North America (RSNA) conference.
In a recent interview, Alexander Rau, M.D., one of the lead authors of the study, discussed key findings from the prospective research that compared 89 patients with long Covid, 38 patients who had a COVID-19 infection but didn’t have long Covid, and 46 patients with no history of COVID-19.
By utilizing diffusion microstructural imaging, Dr. Rau and his colleagues discovered patterns of microstructural gray matter alterations that differed between those with long Covid and those who didn’t have long Covid after having a COVID-19 infection, particularly in basal brain structures.
“There is an impact of COVID-19 on the brain’s microstructure that we could measure with advanced diffusion imaging that was undetectable on conventional (MRI) imaging,” noted Dr. Rau, a resident in the Departments of Neuroradiology and Diagnostic and Interventional Radiology at University Hospital Freiburg in Freiburg, Germany. “Those alterations were associated with post-COVID condition associated symptoms such as fatigue, impaired olfaction, and cognitive decline. Thus, there is evidence that those alterations contribute to the pathophysiology of the post-COVID condition.”
(Editor’s note: For related content, see “MRI Study: People with Past Hospitalization for COVID-19 Have Nearly Triple the Risk of Multiorgan Abnormalities,” “New Meta-Analysis Details Most Common Brain MRI Findings with COVID-19” and “Seven Takeaways from New Consensus Recommendations for Cardiac MRI Assessment of COVID-19.”)
For more insights from Dr. Rau, watch the video below.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.